Microorganisms,
Journal Year:
2022,
Volume and Issue:
10(7), P. 1428 - 1428
Published: July 14, 2022
The
gut
microbiota
(GM)
comprises
billions
of
microorganisms
in
the
human
gastrointestinal
tract.
This
microbial
community
exerts
numerous
physiological
functions.
Prominent
among
these
functions
is
effect
on
host
immunity
through
uptake
nutrients
that
strengthen
intestinal
cells
and
involved
immune
response.
GM
are
not
limited
to
gut,
but
bidirectional
interactions
between
various
extraintestinal
organs
have
been
identified.
These
termed
interorganic
axes
by
several
authors,
which
gut-brain,
gut-skin,
gut-lung,
gut-heart,
gut-metabolism
stand
out.
It
has
shown
an
organism
healthy
or
homeostasis
when
balance.
However,
altered
dysbiosis
represents
a
critical
factor
pathogenesis
many
local
systemic
diseases.
Therefore,
probiotics
intervene
this
context,
which,
according
published
studies,
allows
balance
be
maintained
GM,
leading
individual's
good
health.
Current Nutrition Reports,
Journal Year:
2020,
Volume and Issue:
9(3), P. 171 - 182
Published: May 13, 2020
Abstract
Purpose
of
Review
Probiotics
are
living
bacteria,
which
when
ingested
in
adequate
amounts,
confer
health
benefits.
Gut
microbes
suggested
to
play
a
role
many
psychiatric
disorders
and
could
be
potential
therapeutic
target.
Between
the
gut
brain,
there
is
bi-directional
communication
pathway
called
microbiota-gut-brain
axis.
The
purpose
this
review
examine
data
from
recent
interventional
studies
focusing
on
probiotics
gut-brain
axis
for
treatment
depression,
anxiety
schizophrenia.
Recent
Findings
likely
improve
depression
but
not
Regarding
anxiety,
only
one
trial
showed
an
effect
multispecies
probiotic.
However,
determinants
like
duration
treatment,
dosage
interactions
have
been
thoroughly
investigated
deserve
more
scientific
attention.
Summary
Microbiome-based
therapies
such
as
cautiously
recommended
enhance
beneficial
bacteria
mood
through
FEMS Microbiology Reviews,
Journal Year:
2020,
Volume and Issue:
44(4), P. 454 - 489
Published: May 20, 2020
ABSTRACT
Lactic
acid
bacteria
(LAB)
are
present
in
foods,
the
environment
and
animal
gut,
although
fermented
foods
(FFs)
recognized
as
primary
niche
of
LAB
activity.
Several
strains
have
been
studied
for
their
health-promoting
properties
employed
probiotics.
FFs
potential
beneficial
effects,
which
we
review
this
article.
They
also
an
important
source
LAB,
ingested
daily
upon
FF
consumption.
In
review,
describe
diversity
occurrence
food
well
gut
microbiome.
We
discuss
opportunities
to
study
functional
by
considering
availability
both
genomic
metagenomic
data
public
repositories,
different
latest
computational
tools
analysis.
addition,
role
probiotics
reporting
prevalence
key
features
genomes
surveying
outcomes
use
clinical
trials
involving
human
subjects.
Finally,
highlight
need
further
studies
aimed
at
improving
our
knowledge
link
between
LAB-fermented
from
perspective
health
promotion.
Neurobiology of Disease,
Journal Year:
2019,
Volume and Issue:
136, P. 104714 - 104714
Published: Dec. 15, 2019
Intestinal
inflammatory
disorders
are
associated
with
neurophysiological
and
behavioral
symptoms.
Conversely,
many
of
the
central
nervous
system
(CNS)
accompanied
by
intestinal
complications.
These
observations
suggest
that
physiologies
functionally
linked.
Indeed,
a
growing
body
literature
has
revealed
multiple
pathways
mediating
bidirectional
communication
between
intestine
CNS,
collectively
referred
to
as
gut-brain
axis.
In
particular,
microbes
naturally
colonizing
mammalian
gastrointestinal
(GI)
tract,
termed
gut
microbiota,
not
only
correlate
but
also
play
causative
role
in
regulating
CNS
function,
development
host
behavior.
Despite
these
findings,
our
understanding
cellular
molecular
mechanisms
mediate
remains
its
infancy.
However,
members
microbiota
have
been
established
potent
modulators
intestinal,
systemic
CNS-resident
immune
cell
suggesting
interactions
may
involve
system.
Multiple
associations,
including
neuroinflammatory,
neuropsychiatric
neurodegenerative
disorders,
significant
manifestations.
this
review,
I
discuss
recent
advances
exploring
microbiota-immune
critical
regulator
axis
context
related
disorders.
FEMS Microbiology Reviews,
Journal Year:
2023,
Volume and Issue:
47(2)
Published: March 1, 2023
Abstract
Ruminococcus
gnavus
was
first
identified
in
1974
as
a
strict
anaerobe
the
gut
of
healthy
individuals,
and
for
several
decades,
its
study
has
been
limited
to
specific
enzymes
or
bacteriocins.
With
advent
metagenomics,
R.
associated
both
positively
negatively
with
an
increasing
number
intestinal
extraintestinal
diseases
from
inflammatory
bowel
neurological
disorders.
This
prompted
renewed
interest
understanding
adaptation
mechanisms
gut,
molecular
mediators
affecting
association
health
disease.
From
ca.
250
publications
citing
since
1990,
94%
were
published
last
10
years.
In
this
review,
we
describe
biological
characterization
gnavus,
occurrence
infant
adult
microbiota
factors
influencing
colonization
gastrointestinal
tract;
also
discuss
current
state
our
knowledge
on
role
host
We
highlight
gaps
hypothesis
that
differential
outcomes
are
strain
niche
specific.
Current Opinion in Neurobiology,
Journal Year:
2020,
Volume and Issue:
62, P. 102 - 114
Published: March 9, 2020
A
growing
body
of
evidence
point
toward
the
bidirectional
gut
microbiota-brain
axis
playing
a
role
in
mental
health.
Most
this
research
is
conducted
on
animals
why
we
review
summarize
and
comment
upon
recent
studies
evaluating
microbiome
health
humans.
Further
support
for
relevance
communication
mood
disorders
has
been
presented,
such
as
effect
probiotics
brain
connectivity
outcomes
pregnancy
related
stress
microbiota
newborn
child.
However,
heterogeneity
between
precludes
conclusions
regarding
differences
composition
disease
many
are
limited
by
cross-sectional
design,
small
sample
sizes
multiple
comparisons.
Thus,
well-designed
longitudinal
with
larger
size,
accounting
confounders
needed.
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(9), P. 4494 - 4494
Published: April 19, 2022
An
emerging
body
of
literature
demonstrates
differences
in
the
gut
microbiome
(GMB)
patients
with
major
depressive
disorder
(MDD)
compared
to
healthy
controls
(HC),
as
well
potential
benefits
prebiotic,
probiotic,
and
synbiotic
treatment.
We
conducted
a
systematic
review
24
observational
studies
(n
=
2817),
19
interventional
trials
1119).
assessed
alpha
diversity,
beta
taxa
abundance
changes
MDD
relative
HC,
effect
prebiotics,
probiotics,
synbiotics
on
symptoms
individuals
clinical
or
subclinical
depression.
observed
no
significant
diversity
but
difference
between
HC.
There
were
fluctuations
specific
Probiotic
synbiotic,
not
treatment
showed
modest
benefit
reducing
over
four
nine
weeks.
The
GMB
profiles
differ
significantly
from
further
are
needed
elucidate
probiotic
treatments
antidepressants
longer
follow-up
before
these
therapies
implemented
into
practice.
Translational Psychiatry,
Journal Year:
2022,
Volume and Issue:
12(1)
Published: June 3, 2022
Abstract
A
promising
new
treatment
approach
for
major
depressive
disorder
(MDD)
targets
the
microbiota-gut-brain
(MGB)
axis,
which
is
linked
to
physiological
and
behavioral
functions
affected
in
MDD.
This
first
randomized
controlled
trial
determine
whether
short-term,
high-dose
probiotic
supplementation
reduces
symptoms
along
with
gut
microbial
neural
changes
depressed
patients.
Patients
current
episodes
took
either
a
multi-strain
supplement
or
placebo
over
31
days
additionally
treatment-as-usual.
Assessments
place
before,
immediately
after
again
four
weeks
intervention.
The
Hamilton
Depression
Rating
Sale
(HAM-D)
was
assessed
as
primary
outcome.
Quantitative
microbiome
profiling
neuroimaging
used
detect
MGB
axis.
In
sample
that
completed
intervention
(probiotics
N
=
21,
26),
HAM-D
scores
decreased
time
interactions
between
group
indicated
stronger
decrease
probiotics
relative
group.
Probiotics
maintained
diversity
increased
abundance
of
genus
Lactobacillus
,
indicating
effectivity
increase
specific
taxa.
associated
Finally,
putamen
activation
response
neutral
faces
significantly
Our
data
imply
an
add-on
ameliorates
microbiota
brain,
highlights
role
axis
MDD
emphasizes
potential
microbiota-related
approaches
accessible,
pragmatic,
non-stigmatizing
therapies
Trial
Registration:
www.clinicaltrials.gov
identifier:
NCT02957591.